Moxidectin Enhances Polyene Antifungal Activity via Ergosterol Upregulation in Candida albicans

Study Background and Research Question

Oral candidiasis, primarily caused by Candida albicans, remains a significant clinical challenge, particularly among immunocompromised populations such as the elderly, pediatric patients, individuals with HIV, and those undergoing radiotherapy. Despite the prevalence of polyene antifungals like amphotericin B and nystatin, their clinical use is limited by side effects and suboptimal solubility. The increasing incidence of drug resistance and the lack of new antifungal classes further complicate effective management strategies. The 2024 study by Ye et al. (Applied Microbiology and Biotechnology) addresses whether repositioning moxidectin—a macrocyclic lactone anthelmintic used widely in veterinary antiparasitic protocols—could potentiate polyene activity against C. albicans by modulating fungal sterol metabolism.

Key Innovation from the Reference Study

The pivotal innovation of this study lies in identifying a pharmacological synergy between moxidectin and polyene antifungals, grounded in the upregulation of ergosterol biosynthesis in C. albicans. Ergosterol is the principal target of polyenes; thus, increasing its abundance paradoxically sensitizes the fungus to these agents. The authors demonstrate that moxidectin, beyond its established role in parasitic worm control, can be repurposed to activate the ergosterol biosynthetic pathway in fungal cells, thereby enhancing the fungicidal effects of amphotericin B and nystatin. This mechanistic insight offers a rational approach to combination therapy that may overcome current barriers imposed by resistance and drug toxicity.

Methods and Experimental Design Insights

The researchers employed a multifaceted approach to dissect the interaction between moxidectin and polyene antifungals:

• In vitro synergy assays: Minimum inhibitory concentration (MIC) determination and checkerboard assays evaluated the combined effects of moxidectin with amphotericin B or nystatin against both laboratory strains and 60 clinical isolates of C. albicans.
• Biofilm inhibition: Quantitative and qualitative assessments of biofilm formation were performed under single and combined drug exposures.
• Transcriptomic analysis: RNA-seq and RT-PCR elucidated the impact of moxidectin on the fungal ergosterol biosynthetic pathway, identifying upregulation of key genes.
• Genetic confirmation: Synergy was tested in ergosterol pathway mutants (Δ/Δerg3, Δ/Δerg11, Δ/Δerg3 Δ/Δerg11) to confirm the requirement of ergosterol upregulation for enhanced polyene activity.
• In vivo efficacy: A mouse model of oral candidiasis assessed therapeutic outcomes of moxidectin in combination with low-dose polyenes, measuring fungal burden and mucosal inflammation.

This integrative design allowed the study to link molecular mechanism with translational relevance.

Protocol Parameters

• MIC synergy testing: Moxidectin and polyenes were combined at sub-inhibitory concentrations; precise dosing regimens followed standard CLSI protocols for antifungal susceptibility.
• Biofilm inhibition assay: Biofilms were grown for 24-48 hours with moxidectin, polyenes, or combinations, using crystal violet quantification and confocal imaging.
• Transcriptomic validation: After 6-8 hours of moxidectin exposure, gene expression of ergosterol pathway enzymes was measured by RT-PCR.
• Genetic controls: Use of ergosterol pathway knockout strains to confirm mechanism specificity.
• In vivo oral infection: Mice were infected with C. albicans and treated topically with moxidectin and/or polyenes, monitoring infection area and inflammatory markers on tongue mucosa after 5-7 days.

These parameters enable reproducibility and can be adapted for antifungal combination studies in other fungal pathogens.

Core Findings and Why They Matter

The study's main findings are:

• Moxidectin synergizes with amphotericin B and nystatin to inhibit growth and biofilm formation of C. albicans, including a broad collection of clinical isolates.
• Transcriptome profiling and RT-PCR confirm that moxidectin upregulates key genes in the ergosterol biosynthesis pathway, resulting in elevated ergosterol content in fungal membranes.
• Loss of synergy in ergosterol pathway mutants (Δ/Δerg3, Δ/Δerg11) mechanistically links moxidectin action to ergosterol modulation.
• Combination therapy in a mouse model of oral candidiasis significantly reduces fungal colonization and mucosal inflammation compared to monotherapies (reference study).

These results matter because they reposition a veterinary antiparasitic—previously used for Strongylus vulgaris treatment and Ostertagia ostertagi control—as a potentiator of antifungal therapy. The approach addresses urgent clinical needs by mitigating resistance and reducing required polyene dosages, which may lower toxicity risk.

Comparison with Existing Internal Articles

Several recent articles corroborate and expand upon these findings. For instance, Moxidectin Potentiates Polyenes via Ergosterol Upregulation in Candida emphasizes the mechanistic synergy and its implications for combination therapy design. Similarly, Moxidectin Enhances Polyene Efficacy in Oral Candidiasis Models provides translational rationale for using moxidectin in antifungal research pipelines, highlighting the reproducibility of the ergosterol upregulation effect. Practical workflows and troubleshooting for integrating high-purity moxidectin are detailed in Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal Models, which is especially useful for experimental planning.

Limitations and Transferability

While the reference study demonstrates robust in vitro and in vivo synergy, several limitations merit discussion:

• Host specificity: The findings are currently validated in mouse oral candidiasis models; translation to human clinical scenarios requires further safety and pharmacokinetic studies.
• Mechanistic scope: The synergy is contingent upon an intact ergosterol biosynthetic pathway in C. albicans; its applicability to other fungal species or strains with altered sterol metabolism remains to be established.
• Dosage and administration: Optimal dosing regimens for combination therapy, especially with respect to minimizing polyene toxicity, need systematic investigation.

Nonetheless, the clear mechanistic linkage and the breadth of clinical isolates tested support the transferability of the approach to broader antifungal research.

Why this cross-domain matters, maturity, and limitations

The cross-domain application of moxidectin—a compound originally developed for veterinary antiparasitic use—into antifungal therapy represents a promising avenue for drug repurposing. This strategy leverages established pharmacokinetics and safety profiles in animals and, following the 2018 FDA approval for onchocerciasis in humans, broadens the translational landscape. However, caution is warranted as the antifungal use of moxidectin is still at the preclinical stage, and human-specific toxicology or efficacy data for this indication are not yet available. The maturity of this cross-domain bridge is thus best described as early translational.

Research Support Resources

For laboratories aiming to replicate or extend these findings, reagent quality and workflow consistency are crucial. Researchers can obtain high-purity Moxidectin (SKU B3611) with supporting quality control data for use in combination antifungal studies. Details regarding solubility in ethanol or DMSO, as well as recommended storage conditions (-20°C), can be found in the product information. This resource supports robust experimental design in translational antifungal research.